Physician profile
Sandra M Johnson
NPI 1730198714
$17,441.83
in general payments reported to CMS, 2019-2025
22 companies · $1,473 in 2025
The $1,473 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,023 · 2020: $636 · 2021: $992 · 2022: $1,503 · 2023: $2,519 · 2024: $1,294 · 2025: $1,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,086 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,086.39 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,641.00 | 2019-2022 | |
| Abbvie INC. | $2,224.71 | 2022-2025 | |
| New World Medical,INC. | $1,279.28 | 2019-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Sight Sciences, INC. | $1,275.91 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $1,237.43 | 2020-2025 | Hydrus Microstent, Rocklatan, Centurion |
| Glaukos Corporation | $643.23 | 2023-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $537.57 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $479.28 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $430.87 | 2019-2021 | |
| Ivantis, INC | $349.49 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $315.23 | 2023 | Artevo 800, Quatera 700 |
| Bausch & Lomb Americas INC. | $248.20 | 2022-2025 | Xiidra, Miebo |
| Thea Pharma INC. | $200.00 | 2025 | |
| Eyevance Pharmaceuticals LLC | $149.16 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $120.97 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $73.19 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $51.55 | 2023 | Catalys System |
| Ocular Therapeutix, INC. | $17.65 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $16.44 | 2020 | |
| Boston Scientific Corporation | $14.77 | 2025 | Ams 700 |
| Shire North American Group INC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.